Abstract:Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable treatment responses which have revolutionized oncology. However, despite over 40% of cancer patients being eligible to receive immunotherapy, only 12% of patients gain benefit. A key to understanding what differentiates treatment response from non-response is better defining the role of the innate immune system in anti-tumor immunity and immune tolerance. Teleologically, myeloid cells, including macrophages, dendritic cells, monocytes, and neutrophils, initiate a response to invading pathogens and tissue repair after pathogen clearance is successfully accomplished. However, in the tumor microenvironment (TME), these innate cells are hijacked by the tumor cells and are imprinted to furthering tumor propagation and dissemination. Major advancements have been made in the field, especially related to the heterogeneity of myeloid cells and their function in the TME at the single cell level, a topic that has been highlighted by several recent international meetings including the 2021 China Cancer Immunotherapy workshop in Beijing. Here, we provide an up-to-date summary of the mechanisms by which major myeloid cells in the TME facilitate immunosuppression, enable tumor growth, foster tumor plasticity, and confer therapeutic resistance. We discuss ongoing strategies targeting the myeloid compartment in the preclinical and clinical settings which include: (1) altering myeloid cell composition within the TME; (2) functional blockade of immune-suppressive myeloid cells; (3) reprogramming myeloid cells to acquire pro-inflammatory properties; (4) modulating myeloid cells via cytokines; (5) myeloid cell therapies; and (6) emerging targets such as Siglec-15, TREM2, MARCO, LILRB2, and CLEVER-1. There is a significant promise that myeloid cell-based immunotherapy will help advance immuno-oncology in years to come.

Immune Cells Within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

Role of tumor microenvironment in cancer progression and therapeutic strategy

The Role of Traditional Chinese Medicine in Cancer Immunotherapy: Current Status and Future Directions.

Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy

Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment

Innate Immune Cells in Tumour Microenvironment: A New Frontier in Cancer Immunotherapy

The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Tumor-infiltrating B cells: Their dual mechanistic roles in the tumor microenvironment

Immunocytes interact directly with cancer cells in the tumor microenvironment: one coin with two sides and future perspectives

Advances in targeting tumor microenvironment for immunotherapy

Progress in the Regulation of Immune Cells in the Tumor Microenvironment by Bioactive Compounds of Traditional Chinese Medicine

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses

Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy

Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy

Investigating T Cell Immunity in Cancer: Achievements and Prospects

Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells

The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy

Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies